Search Results for "cyclosporine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for cyclosporine. Results 21 to 30 of 33 total matches.
Maribavir (Livtencity) for Cytomegalovirus Infection (online only)
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
that
are substrates of these pathways, such as tacrolimus
and cyclosporine.
CMV pUL97 kinase is required ...
Maribavir (Livtencity – Takeda), an oral cytomegalovirus
(CMV) pUL97 kinase inhibitor, has been
approved by the FDA for treatment of post-transplant
CMV infection refractory to standard antiviral therapy
in patients ≥12 years old who weigh at least 35 kg.
Low-Dose Colchicine for Coronary Artery Disease
The Medical Letter on Drugs and Therapeutics • Apr 05, 2021 (Issue 1621)
, ritonavir2,
telithromycin
P-gp/moderate CYP3A4 inhibitors amiodarone, cyclosporine,
diltiazem, dronedarone ...
The centuries-old anti-inflammatory drug colchicine
(Colcrys, and others) is FDA-approved for prophylaxis
and treatment of gout flares and for treatment of
familial Mediterranean fever. It is also used off-label
to treat pericarditis, and in recent years has been
investigated for reduction of cardiovascular risk in
patients with coronary artery disease (CAD).
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
The Medical Letter on Drugs and Therapeutics • Oct 03, 2022 (Issue 1660)
, other JAK
inhibitors, or potent immunosuppressants (e.g.,
cyclosporine) may increase the risk of adverse ...
The 1.5% cream formulation of the Janus kinase
(JAK) inhibitor ruxolitinib (Opzelura – Incyte) has
been approved by the FDA for topical treatment of
nonsegmental vitiligo (NSV) in patients ≥12 years old.
Opzelura is the first product to be approved by the
FDA for this indication. It was previously approved for
treatment of atopic dermatitis.
Relyvrio for ALS
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
, such as cyclosporine, can increase
levels of conjugated bile salts in the liver and is not
recommended. Use ...
The FDA has approved Relyvrio (Amylyx), a fixed-dose
combination of sodium phenylbutyrate and
taurursodiol, for treatment of amyotrophic lateral
sclerosis (ALS). Sodium phenylbutyrate (Buphenyl,
and others) has been available by prescription
for years for treatment of urea cycle disorders.
Taurursodiol (tauroursodeoxycholic acid), a derivative
of ursodiol, is an over-the-counter bile acid
supplement claimed to have neuroprotective
benefits. Relyvrio is the third drug to be approved
in the US for treatment of ALS; riluzole (Rilutek, and
others) and edaravone (Radicava, Radicava...
Comparison Table: Some Lipid-Lowering Drugs (online only)
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022 (Issue 1659)
these transporters
▶ Cyclosporine increases statin serum concentrations and the risk of
rhabdomyolysis, probably ...
View the Comparison Table: Some Lipid-Lowering Drugs
Atogepant (Qulipta) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
or cyclosporine,
can increase atogepant serum concentrations and
concurrent use of a strong CYP3A4 inducer can ...
Atogepant (Qulipta – Abbvie), an oral small-molecule
calcitonin gene-related peptide (CGRP) receptor
antagonist ("gepant"), has been approved by the
FDA for prevention of episodic migraine in adults. It
is the second oral CGRP receptor antagonist to be
approved in the US for this indication; the first was
rimegepant (Nurtec ODT), which is also approved
for acute treatment of migraine. Parenteral CGRP
monoclonal antibodies are approved for prevention
of migraine (see Table 3).
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
in patients with comorbid
eosinophilic asthma. Cyclosporine is sometimes
used off-label for treatment ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction
Drugs for Gout
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
inhibitor such
as clarithromycin (Biaxin, and others) or a strong P-gp
inhibitor such as cyclosporine ...
Drugs for gout are used to reduce the pain and
inflammation of acute flares, decrease the frequency
of exacerbations, and lower serum urate levels to
prevent recurrent flares, development of tophi, and
joint damage.
Med Lett Drugs Ther. 2023 Oct 30;65(1688):169-75 doi:10.58347/tml.2023.1688a | Show Introduction Hide Introduction
Comparison Table: Some Drugs for Gout (online only)
The Medical Letter on Drugs and Therapeutics • Oct 30, 2023 (Issue 1688)
of
cyclosporine
Can prolong the half-life of
chlorpropamide
May increase frequency of skin rash in
patients ...
View the Comparison Table: Some Drugs for Gout
Med Lett Drugs Ther. 2023 Oct 30;65(1688):e176-9 doi:10.58347/tml.2023.1688c | Show Introduction Hide Introduction
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • May 30, 2022 (Issue 1651)
in coagulation parameters. Cyclosporine
serum concentrations may be reduced when
coadministered with orlistat ...
Adults with a body mass index (BMI) between 25
and 29.9 kg/m2 are considered overweight. Those
with a BMI ≥30 are considered obese. The initial
recommendation for any weight loss effort is to
achieve a 5-10% reduction in weight, which has been
associated with a reduction in the risk of developing
type 2 diabetes, hypertension, and dyslipidemia. Diet,
exercise, and behavior modification are the preferred
methods for losing weight, but long-term weight
maintenance can be difficult. Several drugs and
devices are FDA-approved for weight reduction and
maintenance of weight...